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Anaemia is considered a common problem in
many cancers secondary to the disease itself or re-
lated to chemo- and/or radiotherapy. Several clin-
cal trials have advocated the prognostic value of
anaemia and hypoxia in the outcome of many can-
cers. Erythropoietin is recognised as an effective
treatment for anaemia, which also improves the
quality of life in patients with malignant disease.
External radiotherapy plays an important role in
the treatment of loco-regional cancer but its effi-
cacy can be compromised by many factors. Tumor
hypoxia is considered by many authors as an im-
portant factor contributing to radioresistance. We
report in this article the radiobiological rationale
in favour of combining radiotherapy and erythro-
poietin, and review relavant clinical papers pub-
lished in this field.
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Anaemia is commonly seen in a variety of can-
cers at various stages of progression. It may be sec-
ondary to the cancer or associated with myelotoxic
regimens such as chemotherapy and/or external
radiotherapy [1–3].
The prevalence and effects of anaemia were
long disregarded by oncologists. Over the last few
years, numerous papers reporting from this field
have pointed out the prognostic value of anaemia
and the adverse effects of tumour hypoxia on the
efficacy of anticancer treatments, in this way pro-
moting resistance to radiotherapy and/or chemo-
therapy. 
Retrospective studies show that patients with
satisfactory haemoglobin levels receiving external
radiotherapy primarily for cancers of the cervix
[4–6] and head and neck cancers [7–9] have better
loco-regional tumour control and better overall
survival. 
External radiotherapy is of paramount impor-
tance in loco-regional cancer treatment. Its success
may be compromised by the presence of demon-
strably unfavourable factors such as tissue hypoxia
and a low haemoglobin level [10–12].
In combination with iron supplementation,
recombinant human erythropoietin (rhuEPO) is
recognised as effective for treating anaemia in can-
cer patients on chemotherapy. The use of rhuEPO
has been demonstrated to have a sustained benefi-
cial impact on patient quality of life [13–17]. It has
been studied in randomised phase I/II and phase
III trials in combination with external radiother-
apy with or without chemotherapy by a number of
research teams. A recently published study de-
scribes the beneficial impact of a weekly dose of
40000 IU of rhuEPO on quality of life in chemora-
diotherapy recipients [18].
This paper presents radiobiological argu-
ments in favour of combining external radiother-
apy and rhuEPO and provides a critical review of
clinical papers published in this field.
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Most radio-oncology departments use linear
accelerators producing indirectly ionising X rays.
Passing through matter, the radiation provokes a
series of physicochemical reactions caused by
water radiolysis, giving rise to the formation of free
radicals which, in the presence of oxygen, fixes the
damage in tumour cells by breaking double-
stranded DNA [19]. Oxygen must be present in
sufficient quantities in the intracellular milieu dur-
ing irradiation in order to act as a powerful sensi-
tiser of cells to the effects of radiation. Hence, the
extent of the biological effect of radiotherapy cor-
relates positively with the oxygen concentration. 
Research work by Thomlinson and Gray in
the 1950s showed that hypoxia is a factor involved
in radiation tolerance [20]. The external radiother-
apy (RT) doses must be multiplied by a factor of 
3 to eradicate hypoxic tumour cells and thus to 
obtain the same biological effect versus normally
oxygenated cells. This phenomenon is known by
the term oxygen enhancement ratio (OER) [19].
Anaemia plays a complex role in the inter-
action between tumour hypoxia and stimulation 
of angiogenesis. Hypoxia induces the expression of
various angiogenic cytokines (VEGF, bFGF, IL-8,
TNF, etc), responsible in the course of various sig-
nal transduction cascades for the proliferation, mi-
gration and differentiation of the endothelial cells
responsible for the development of neovasculature
in a tumour. As the tumour increases in size, so do
the hypoxic areas and the angiogenic signals re-
sponsible for development and metastasis increase
[21].
On the basis of experimental models, it is sug-
gested that tumour hypoxia in the tissues arises
when partial oxygen pressure in the venous end of
capillaries declines below 45–50 mm Hg [22]. To
demonstrate the correlation between anaemia and
hypoxia, Groebe et al., having validated the perti-
nent parameters – including blood flow, arterial
partial pressure (90–100 mm Hg) at a haemo-
globin level of 14 g/dl – were able to induce ar-
terial hypoxia and raise hypoxia levels in tumour
tissue in the presence of haemoglobin levels below
10 g/dl [23].
Hypoxia, therefore, induces cell resistance
mechanisms both to radiotherapy as indicated
above, and also to chemotherapy agents. Hypoxia
gives rise to inhibition of cellular proliferation by
an accumulation of cells in phase G0 of the cell
cycle. It reduces cytotoxicity, induces hypoxic
stress proteins, lowers the apoptotic potential and
causes tissue acidosis [24].
Hypoxia was recently shown to be responsible
for increasing the instability of tumour cell DNA,
resulting in the development of cell clones with a
low apoptotic potential and high metastatic poten-
tial [25–27].
This narrow link between tumour oxygena-
tion and haemoglobin levels is proof of the impor-
tance of treating anaemia. Rectification of this
anaemia before or during external RT with cura-
tive-intent might help to increase loco-regional
control of the cancer and, in the best of cases,
improve overall survival.
Radiobiological rationale
Ways to overcome tumour hypoxia and anaemia during radiotherapy
Blood transfusion prior to irradiation was the
traditional approach to rectifying anaemia, but
various studies have failed to disclose a significant
effect in spite of increased haemoglobin concen-
trations [28]. Overgaard et al. conducted a ran-
domised trial to investigate the effects of a ra-
diosensitiser (nimorazole) and evaluate the rectifi-
cation of anaemia by blood transfusions in patients
with head and neck cancers [29]. The authors ob-
served a statistically significant correlation be-
tween the pre-radiotherapy haemoglobin level and
local tumour control. On the other hand, no dif-
ference was found in terms of local control be-
tween transfused (39%) and non-transfused sub-
jects (35%). The authors explained these results by
the fact that tumour growth starts before irradia-
tion and postulated the advisability of progres-
sively raising the haemoglobin level during radio-
therapy. The results indicate the importance of
stratifying patients according to their baseline
haemoglobin level in future randomised trials.
Other studies were based on the concept of
combining different hypoxia-modifying agents
during curative-intent irradiation of head and neck
cancers [29–31]. A Danish group conducted sev-
eral in vitro and in vivo studies on a number of ra-
diosensitising agents. In the DAHANCA protocol
5–85, nimorazole displayed benefits both in terms
of local control and disease-free survival in cancers
of the pharynx and larynx [29]. Lee et al. investi-
gated the role of etanidazole in a randomised study
involving subjects with head and neck cancer [31].
The fate of 289 patients was reported in relation
to their baseline haemoglobin levels prior to irra-
diation. Five-year survival was 36% in the non-
anaemic group versus 22% in the anaemic group.
Other drugs (metronidazole) have been aban-
doned because of their peripheral neurotoxicity
[32].
Although hyperbaric oxygenation has the po-
tential to improve response to radiotherapy, as
demonstrated in experimental tumour models
[33], logistics and technical difficulties limit the
routine use of hyperbaric oxygen in radiotherapy
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[34]. In our view similar difficulties hamper the
routine use of artificial blood in anaemic cancer pa-
tients undergoing radiotherapy.
Agents that either reduce the oxygen binding
capacity of haemoglobin (eg, efaproxiral) or mod-
ify the haemorrheologic characteristics (eg, pen-
toxifylline) have shown the potential to increase
tissue oxygenation and radiosensitivity [35, 36].
However, extensive clinical data are lacking.
The use of rhuEPO in combination with iron
in the treatment of anaemia has emerged as a new
alternative approach capable of gradually increas-
ing the haemoglobin level before and/or during ra-
diotherapy [37, 38].
Combination of external radiotherapy (RT), erythropoietin (rhuEPO) 
and iron
Phase I-II clinical trials
The first phase I trial was reported by Lavey
et al. from the University of California, Los Ange-
les and involved forty non-metastatic patients pre-
senting with different types of localised supradi-
aphragmatic cancers [39]. Subjects with a haemo-
globin level below 13.5 g/dl and scheduled to un-
dergo external radiotherapy (RT) for a period of 5
to 8 weeks were eligible for the study. Recombi-
nant huEPO (epoetin alfa) was injected subcuta-
neously at a dose of 150–300 IU/kg three times a
week. This treatment was administered for 10 days
before starting RT in a group of 20 patients. The
other group served as a control arm. The entire
study population received iron sulphate supple-
mentation per os. This study demonstrated a 6%
increase in haemoglobin level during RT in the
rhuEPO group, rising from 11.9 ± 1.3 to more than
14 g/dl in 80% of subjects in the rhuEPO group
versus 5% in the control arm. Recombinant
huEPO was excellently tolerated.
Vijayakumar et al. carried out a randomised
phase II study in 26 patients with various solid tu-
mours (lungs, breast, cervix and prostate). The first
group received radiochemotherapy on its own (to
match their primary tumour), and the second
group received rhuEPO in addition (epoetin alfa;
200 IU/kg Monday to Friday) and iron sulphate
per os. The protocol permitted reducing the dose
to 100 IU/kg if haemoglobin levels rose above 
15 g/dl in men and above 14 g/dl in women. In the
2nd group, haemoglobin levels rose by 0.43 g/dl 
per week. The authors recommend administering
rhuEPO several weeks before starting radiother-
apy [40].
Dusenbery et al. evaluated the efficacy of
rhuEPO (epoetin alfa) in 20 patients with resected
epidermoid carcinoma of the cervix and haemo-
globin levels below 12.5 g/dl [41]. rhuEPO was ad-
ministered at a dose of 200 IU/kg/day in combina-
tion with iron sulphate. This treatment was started
5–10 days before initiating RT. The results show 
a 30% increase in haemoglobin levels during RT
in the rhuEPO group, rising from 10.3 ± 1.04 to
13.2 ± 1.7 g/dl. Two patients developed deep vein
thrombosis as a side effect 9 to 10 days after finish-
ing RT treatment and rhuEPO. 
Henke et al. randomised 50 patients with head
and neck or cervical cancer to one of four differ-
ent rhuEPO dosing regimens (epoetin alfa or epo-
etin beta; 150 IU/kg week i.v., 300 IU/kg/week i.v.,
150 IU/kg/week s.c., and one group with no treat-
ment). Haemoglobin levels rose 0.7 g/dl/week in
rhuEPO recipients with a significant correlation
between the increase in haemoglobin levels and
local control regardless of the specific rhuEPO
dosing regimen [42].
In these prospective clinical trials, rhuEPO
administered at a dose of between 150 and 300
IU/kg 3 times per week in combination with iron
substitution (strict supplementation) is effective in
achieving a haemoglobin level of 12 to 14 g/dl
during external RT in 80% of patients. Tolerance
is acceptable apart from rare cutaneous reactions
(at the injection site) and rare deep venous throm-
bosis, mainly at haemoglobin-levels exceeding the
recommended target level of 12 g/dl [43].
Phase III clinical trials
Glaser et al. performed an uncontrolled trial
in 60 patients diagnosed with T2–4 N0–2 cancers
of the oral cavity and haemoglobin levels below
12.5 g/dl [44]. The treatment was composed of a
combination of external RT (total dose of 50 Gy)
and chemotherapy (mitomycin C and 5-fluoro-
uracil) followed by surgery at week 10. One arm
received rhuEPO (epoetin alfa) at a dose of 150
IU/kg s.c. three times per week. The protocol
epoetin beta placebo
n (%) n (%)
Sex (male) 158 (88%) 145 (85%)
Smokers* 118 (66%) 91 (53%)
Hypopharynx 40 (22%) 43 (25%)
Stage III (AJCC) 37 (21%) 46 (27%)
Stage IV (AJCC) 135 (75%) 123 (72%)
Relapsed patients 18 (10%) 13 (8%)
*p <0.05 (significantly more smokers in the epoetin beta group).
Table 1
Certain demographic
characteristics of pa-
tients in Henke’s
study [47].
epoetin beta arm placebo arm 
(n = 40) (n = 43)
Sex (male) 90% 86%
Smokers 55% 44%
Stage IV (AJCC) 85% 70%
Relapsed patients 15% 8%
Table 2
Characteristics of the
subgroup of patients
with cancer of the 
hypopharynx in
Henke’s study [47].
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allowed the dose to be doubled in subjects whose
weekly haemoglobin increase was below 0.3 g/dl.
No iron supplementation was prescribed in this
study. The complete response rate after neoadju-
vant treatment was 63% in the rhuEPO group
versus 27% in the non-rhuEPO group. Overall
survival (90% vs. 60%; p = 0.03) and loco-regional
control (90% vs. 63%; p = 0.03) at 2 years were
significantly superior in the rhuEPO arm. This
was the first study to show the efficacy of rhuEPO
in combination with neoadjuvant radiochemo-
therapy but the control arm was based on compar-
ison with a historical cohort. 
The same Viennese group published the re-
sults of a retrospective study in 191 patients which
probably included the data from the controlled
trial described above [45].
A study reported by Blohmer et al. [46] inves-
tigated the impact of rhuEPO combined with iron
in high-risk patients with cervical cancer. The
patients underwent hysterectomy followed by
radiochemotherapy combined with epoetin alfa
(310000 IU/week) versus standard care and
transfusions as needed. rhuEPO treatment re-
duced the number of anaemic patients (p = 0.001)
and lowered the number of transfusions (p <0.02)
and kept haemoglobin levels above 12 g/dl despite
radiochemotherapy. The relapse rate was lower in
the rhuEPO arm (17% versus 25%, p <0.07) than
in the control arm. This is shown in figure 1.
A phase III trial testing the efficacy of com-
bined rhuEPO (epoetin beta) and external RT was
recently published [47]. Henke et al. randomised
351 patients with epidermoid carcinoma located in
the oral cavity, oropharynx, hypopharynx or larynx
with haemoglobin levels below 12.0 g/dl (for
women) or 13.0 g/dl (for men). Subjects with ex-
ternal curative-intent RT (postoperative or on its
own) were eligible to take part in this randomised,
multicentre, double-blind trial. The first group of
180 patients received epoetin beta at a dose of 300
IU/kg s.c. 3 times per week, administered from day
14 to day 10 before RT, during and upon comple-
tion of irradiation. The other group of 171 patients
received placebo by the subcutaneous route. The
study prescribed weekly iron supplementation by
the intravenous route (200 mg of iron saccharate
or 187.5 mg of iron gluconate) in subjects with a
transferrin saturation remaining below 25%, or,
alternatively, iron supplementation by mouth.
None of the patients received chemotherapy.
Loco-regional progression-free survival was the
primary endpoint of the study. Time to loco-
regional progression and overall survival were
evaluated as secondary endpoints in this trial.
The results of this study were surprising in
that, despite an increase in haemoglobin levels to
>14 g/dl in women and >15 g/dl in men, the vari-
ous outcome measures analysed – namely, loco-
regional progression-free survival, time to pro-
gression, and overall survival – were inferior in the
experimental arm. 
A number of points have been raised in con-
nection with this trial [48]. Firstly, the results were
negative and indeed contradictory compared with
studies conducted by other teams. Secondly,
58/171 (34%) of the placebo patients and 79/180
(56%) of the EPO group were protocol violators.
Only 73% of the total study population were
treated as stipulated in the protocol. The results
obtained in the patients abiding by the protocol
revealed no difference as regards survival or loco-
regional control. Thirdly, TNM grading and per-
formance index of the patients involved were not
described by the authors though these are predic-
tive of prognosis in head and neck cancers. Finally,
an imbalance between the two arms was probably
a crucial factor in this study. Table 1 outlines the
various characteristics of the patients in this trial
and shows that the epoetin beta group contained a
significantly higher percentage of smokers in com-
parison with the control group. Recent publica-
tions report the presence of higher risk cancers in
smokers [49] and poorer survival rates in cancer
patients who continue smoking during chemora-
diotherapy [50]. The latter observation could be
related to the fact that carboxyhaemoglobin, found
in increased concentrations in the blood of smok-
ers, reduces the amount of oxygen that can be
carried to the tissues, thereby increasing tumour
hypoxia and reducing the effectiveness of ionising
irradiation [51]. Table 2 summarises the character-
istics of the subgroups of patients with cancer of
the hypopharynx, a localisation known to be asso-
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Figure 1
Recurrence-free
survival in subjects
with high-risk
cervical cancer on
chemotherapy receiv-
ing transfusions or
epoetin alfa for treat-
ment of anaemia [46]
(reproduced with per-
mission).
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Figure 2
Haemoglobin level
and tumour oxygena-
tion: optimum tu-
mour oxygenation 
in carcinoma of the
vulva is obtained 
in subjects with a
haemoglobin level 
of 13.8 g/dl [52] 
(reproduced with 
permission).
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ciated with a worse prognosis than other head and
neck cancer sites. The percentage of smokers, sub-
jects with stage IV disease and relapse was higher
in the epoetin beta group than in the placebo
group. The presence of these risk factors in sub-
jects with hypopharyngeal cancer in the epoetin
beta group probably caused an imbalance between
the two groups which would explain the negative
impact in the rhuEPO treatment arm. Regrettably,
the subgroup analysis was not initially scheduled
in this trial. Owing to the limited number of pa-
tients analysed in these subgroups, no significant
conclusions can be drawn. The median haemo-
globin level rose from 11.7 g/dl to a mean level of
14.8 g/dl at 4 weeks in the epoetin beta group, pos-
sibly explaining a higher incidence of vascular
complications (hypertension, haemorrhage, venous
thrombosis, pulmonary embolism and cerebrovas-
cular accidents) in the epoetin beta group (11%
versus 5%). In general, major toxicity was compa-
rable in the two study arms (8% in the rhuEPO
arm versus 6% in the placebo arm). There were
also 10 cardiac deaths in the experimental arm
compared to 5 in the placebo arm [47]. Is epoetin
beta justified in patients with haemoglobin levels
above 14.0 g/dl who are not receiving treatments
known to be myelotoxic?
The authors conclude that: 1) Despite the 
increase in haemoglobin levels, treatment with
rhuEPO demonstrated no impact on loco-regional
progression-free survival, loco-regional progres-
sion, and global survival in an intent-to-treat
analysis (excluding no patients) in subjects with
head and neck cancer; 2) this study does not con-
firm the hypothesis of a radiosensitising effect of
rhuEPO, and 3) more studies are necessary in
order to analyse the effect of rhuEPO treatment
on cancer control and survival [47].
This study came in for widespread criticism, as
evidenced by the number of letters to the editor in
response to its publication [48]. Although the
points raised by the various authors have been out-
lined above, we would nevertheless like to present
in greater detail the hypothesis supported by Vau-
pel et al. regarding a link between haemoglobin
levels and intratumoral pO2 [52]. The latter au-
thors showed that optimum intratumoral oxygena-
tion in patients with gynaecological cancers is
associated with haemoglobin levels ranging from
12 to 14 g/dl (fig. 2). Haemoglobin levels above 
14 g/dl are associated with a decline in tumour oxy-
genation, probably attributable to declining blood
perfusion owing to higher viscosity. Extrapolation
of the hypothesis tendered by Vaupel et al. [52] to
the results of the study by Henke et al. [47] pro-
vides a likely explanation for the harmful effect
seen in the rhuEPO arm. The patients in the
placebo arm had a median haemoglobin level of
12.9 g/dl compared with 15.4 g/dl in the experi-
mental arm. The haemoglobin concentration
achieved in the placebo arm would have been suf-
ficient if the aim of the study were to reduce the
hypoxic fraction of the tumour. Any additional rise
in haemoglobin levels might have compromised
the beneficial effect. The role and function of EPO
receptors is unknown at this time. Studies are
under way to investigate the effect of rhuEPO on
tumour cell lines expressing EPO receptors. New
clinical trials would be desirable to answer this
question.
Limitations to the use of rhuEPO?
The additional cost of using rhuEPO to treat
anaemia in cancer patients undergoing external
radiotherapy has not been specifically addressed so
far. When comparing the use of rhuEPO to red
blood cell transfusions, however, a study by
Cremieux et al. [53] indicated that rhuEPO (in
conjunction with transfusion) may be about 20%
more cost effective than transfusions alone (in
terms of the cost to achieve a specified improve-
ment in haemoglobin-level). In addition, rhuEPO
can prevent the occurrence of anaemia in many
non-anaemic patients with cancer and at risk of de-
veloping anaemia under treatment. These patients
would normally not be transfused unless the
haemoglobin-level has dropped to low levels, eg,
<8 g/dL. In contrast to the current “best standard
of care”, including red-blood cell transfusions as
needed, the use of rhuEPO results in sustained im-
provements in quality of life, whereas the effect of
transfusions is not sustained beyond 2 weeks [16,
17]. Finally, it has to be taken into account that the
supply of donor blood is limited. The recent inter-
vention of the Swiss health authorities aiming at a
prevention of the spread of variant Creutzfeldt-
Jacob disease through blood donors will increase
the shortage of donated blood, necessitating its
restricted use in carefully selected patients.
In the year 2002, the rare occurrence of anti-
body-mediated pure red cell aplasia (PRCA) in pa-
tients suffering from renal insufficiency and un-
dergoing treatment with rhuEPO was reported
[54]. It is known from the literature that all exoge-
nously dosed proteins can induce an immunogenic
response with antibody production, especially
when given subcutaneously [55]. RhuEPO-in-
duced PRCA in patients with renal insufficiency
has been reported worldwide and with all
rhuEPO-products and preparations. For epoetin
alfa, a temporary increase in PRCA-incidence in
patients with renal insufficiency was observed
since 1998 with a peak in 2002 [54]. For (radio-)
oncologists it is important to note that despite
intense surveillance, no cases of PRCA in the other
registered indications of epoetin alfa, eg, in oncol-
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ogy, have been reported. Several measures were
taken (eg, intravenous administration in patients
with renal insufficiency), and an investigation was
started to identify the cause of this phenomenon.
Recently the most likely cause was identified:
chemicals released from the rubber stoppers of
prefilled syringes acted as an immunological adju-
vant [56]. The rubber stoppers were only used for
epoetin alfa syringes (outside the USA) and they
have been replaced by Teflon stoppers. The
PRCA-incidence for epoetin alfa in patients with
renal insufficiency is again at the very low level
reported until 1998. 
Conclusions
Recombinant-huEPO in combination with
iron is definitely effective in treating anaemia
during chemotherapy or radiochemotherapy in
subjects with solid tumours. 
The improvement of loco-regional control of
head and neck cancers achieved by RT depends on
a number of prognostic factors, including the un-
derlying tumour, tissue environment, and patient
on the one hand, and, on the other hand, various
factors concerned with the irradiation process it-
self. 
In experimental models, treating anaemia with
rhuEPO improves tumour response to radiation
treatment [57–60]. The same applies to cytotoxic
treatment such as cyclophosphamide whose action
depends on the presence of oxygen, where
rhuEPO restores chemosensitivity [61].
A phase III prospective study launched by
EORTC (22996) was intended to randomise sub-
jects with head and neck cancer treated with RT
alone to receive rhuEPO-based treatment versus
placebo. We regret the early termination of this
study due to inadequate recruitment, as it would
have answered some of the questions raised above.
The role of combination rhuEPO-external radio-
therapy remains inconclusive; new clinical trials
based on clearly defined criteria are required to
demonstrate its importance. 
In the meantime, treatment of treatment- or
tumour-related, symptomatic anaemia using blood
transfusion and/or rhuEPO remain still an appro-
priate means of enhancing the quality of life of
cancer patients.
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